[IOICORP] QoQ Annualized Quarter Result on 31-Mar-2020 [#3]

Stock
[IOICORP] IOI CORPORATION BHD
Announcement Date
27-May-2020
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2020
Quarter
31-Mar-2020 [#3]
Profit Trend
QoQ- -33.31%
YoY- -38.03%
Quarter Report
Latest QR
Upcoming QR
IOICORP's Result
IOICORP's Financial Summary
View:
Show?
Annualized Quarter Result
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Revenue 9,863,800 9,908,800 7,802,200 7,686,133 7,461,400 7,102,000 7,385,600 21.16%
PBT 1,580,400 1,440,800 826,700 694,000 935,800 794,400 872,600 48.31%
Tax -289,200 -309,600 -225,000 -208,000 -212,600 -203,600 -255,000 8.71%
NP 1,291,200 1,131,200 601,700 486,000 723,200 590,800 617,600 63.13%
-
NP to SH 1,267,200 1,111,600 600,900 483,466 725,000 596,000 631,700 58.72%
-
Tax Rate 18.30% 21.49% 27.22% 29.97% 22.72% 25.63% 29.22% -
Total Cost 8,572,600 8,777,600 7,200,500 7,200,133 6,738,200 6,511,200 6,768,000 16.98%
-
Net Worth 9,587,591 9,212,196 9,275,752 8,921,291 9,301,273 9,489,812 9,301,273 2.03%
Dividend
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Div 563,976 - 501,392 335,072 502,771 - 502,771 7.92%
Div Payout % 44.51% - 83.44% 69.31% 69.35% - 79.59% -
Equity
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Net Worth 9,587,591 9,212,196 9,275,752 8,921,291 9,301,273 9,489,812 9,301,273 2.03%
NOSH 6,285,198 6,285,038 6,285,038 6,285,038 6,284,643 6,284,643 6,284,643 0.00%
Ratio Analysis
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
NP Margin 13.09% 11.42% 7.71% 6.32% 9.69% 8.32% 8.36% -
ROE 13.22% 12.07% 6.48% 5.42% 7.79% 6.28% 6.79% -
Per Share
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
RPS 157.41 158.12 124.49 122.34 118.72 113.01 117.52 21.40%
EPS 20.22 17.72 9.57 7.69 11.54 9.48 10.05 59.03%
DPS 9.00 0.00 8.00 5.33 8.00 0.00 8.00 8.13%
NAPS 1.53 1.47 1.48 1.42 1.48 1.51 1.48 2.22%
Adjusted Per Share Value based on latest NOSH - 6,285,038
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
RPS 157.62 158.34 124.67 122.82 119.23 113.48 118.02 21.16%
EPS 20.25 17.76 9.60 7.73 11.58 9.52 10.09 58.77%
DPS 9.01 0.00 8.01 5.35 8.03 0.00 8.03 7.94%
NAPS 1.532 1.472 1.4822 1.4256 1.4863 1.5164 1.4863 2.03%
Price Multiplier on Financial Quarter End Date
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Date 31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 28/06/19 -
Price 4.37 4.46 4.34 4.00 4.61 4.43 4.25 -
P/RPS 2.78 2.82 3.49 3.27 3.88 3.92 3.62 -16.07%
P/EPS 21.61 25.14 45.27 51.98 39.96 46.71 42.28 -35.94%
EY 4.63 3.98 2.21 1.92 2.50 2.14 2.37 55.95%
DY 2.06 0.00 1.84 1.33 1.74 0.00 1.88 6.25%
P/NAPS 2.86 3.03 2.93 2.82 3.11 2.93 2.87 -0.23%
Price Multiplier on Announcement Date
31/12/20 30/09/20 30/06/20 31/03/20 31/12/19 30/09/19 30/06/19 CAGR
Date 23/02/21 16/11/20 25/08/20 27/05/20 18/02/20 26/11/19 15/08/19 -
Price 4.24 4.51 4.55 4.50 4.50 4.45 4.23 -
P/RPS 2.69 2.85 3.65 3.68 3.79 3.94 3.60 -17.58%
P/EPS 20.97 25.43 47.46 58.48 39.01 46.92 42.08 -37.01%
EY 4.77 3.93 2.11 1.71 2.56 2.13 2.38 58.62%
DY 2.12 0.00 1.76 1.19 1.78 0.00 1.89 7.91%
P/NAPS 2.77 3.07 3.07 3.17 3.04 2.95 2.86 -2.09%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment